Biomaterials. 2018 Apr 16;171:34-45.

Limitation of current anti-Vascular Endothelial Growth Factor (VEGF) cancer therapy is transitory responses, inevitable relapses and its insufficient tumor-targeting. Thus, multifaceted approaches, including the development of bispecific antibodies and combination strategies targeting different pathways have been proposed as an alternative. Here, we developed a novel multi-paratopic VEGFdecoy receptor, Cetuximab-VEGF-Grab and Trastuzumab-VEGF-Grab, by genetically fusing VEGF decoy receptor (VEGF-Grab) to a single chain Fv of anti-Epidermal Growth Factor Receptor (EGFR) antibody (Cetuximab and Trastuzumab). These multi-paratopicVEGF decoy receptor, which recognize VEGF and EGFR family (EGFR or HER2), effectively suppressed both VEGF and EGFR pathways in vitro, to levels similar to those of the parental VEGF-Grab and anti-EGFR antibodies. In addition, the concurrent binding of multi-paratopic VEGF decoy receptor to VEGF and EGFR family enabled their specific localization to EGFR + tumor in vitro and in vivo. Furthermore, Cetuximab-VEGF-Grab and Trastuzumab-VEGF-Grab exhibited the enhanced anti-tumor activities compared to VEGF-Grab in EGFR + tumor xenograft mouse model via anti-EGFR and the targeted anti-angiogenic activities. These results indicate that multi-paratopic VEGF decoy receptor can be a promising agent, combining tumor-targeted anti-angiogenic therapy with efficient blockade of proliferative signals mediated by EGFR family.


Please reload


61. Kang JI, Choi Y, Cui C-H, Lee D*, Kim SC*, Kim HM*. Pro-angiogenic Ginsenosides F1 and Rh1 inhibit Vascular Leakage by Modulating NR4A1. Sci Rep. 2019, 2019 Mar 14;9(1):4502.

60. Won SY, Lee P, Kim HM*. Synaptic organizer: Slitrks and type IIa receptor protein tyrosine phosphatases. Curr Opin Struct Biol. 2019 Feb; 54:95-103.


59. Kwon MJ, Han MH, Bagley JA, Hyeon DY, Ko BS, Lee YM, Cha IJ, Kim SY, Kim DY, Kim HM, Hwang D, Lee SB, Jan YN. Coiled-coil structure dependent interactions between polyQ proteins and Foxo lead to dendrite pathology and behavioral defects. Proc Natl Acad Sci U S A. 2018 Oct 22. pii: 201807206.

58. Kim HM*, Kim YM*. HMGB1: LPS Delivery Vehicle for Caspase-11-Mediated Pyroptosis (Preview). Immunity. 2018 Oct 16;49(4):582-584.

57. Yoon HR, Choi H, Choi YA, Kim JA, Jung J, Kim HM, Jung Y. Fabrication of Oligomeric Avidin Scaffolds for Valency-Controlled Surface Display of Functional Ligands. Angew Chem Int Ed Engl. 2018 Sep 17;57(38):12410-12414. 

56. Won SY, Kim HM*. Structural Basis for LAR-RPTP-Mediated Synaptogenesis. Mol Cells. 2018 Jul 31;41(7):622-630.

55. Lee J-H, Park BS, Han KR, Biering SB, Kim SJ, Choi J, Seok JH, Alam I, Chung MS, Kim HM, Hwang S, Kim KH. Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol. 2018 Jul 03;9:1466.

54. Lee DH, Lee MY, Seo Y, Hong HJ, An HJ, Kang JS*, Kim HM*. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities. Biomaterials. 2018 Apr 16;171:34-45.

53. Seo BA, Lee JH, Kim HM*, Kang MG*. Neuronal calcium channel α1 subunit interacts with AMPA receptor, increasing its cell surface localization. Biochem Biophys Res Commun. 2018 Apr 6;498 (3):402-408.

52. Ahn B, Lee S-G, Yoon HR, Lee JM, Oh HJ, Kim HM*, Jung Y*. Four-fold Channel-Nicked Human Ferritin Nanocages for Active Drug Loading and pH-Responsive Drug Release. Angew Chem Int Ed Engl. 2018 Mar 5;57(11):2909-2913.


51. Kim SY, Jeong JM, Kim SJ, Seo W, Kim MH, Choi WM, Yoo W, Lee JH, Shim YR, Yi HS, Lee YS, Eun HS, Lee BS, Chun K, Kang SJ, Kim SC,7, Gao B, Kunos G, Kim HM, Jeong WI. Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4-MD2 complex. Nat Commun. 2017 Dec 21;8(1):2247.


Please reload